Fall 2017 Investor Presentation
Legal Disclaimer & Forward Looking Information CSE: VRT | OTC:VRTHF | FRT:2VP LEGA GAL DISCLAIMER : This document provides a description of Veritas Pharma Inc. (“Company” or the “Company”) and its business. Prospective investors are encouraged to obtain independent legal advice concerning any investment in securities of Company and should not base their decision on whether to invest in Company solely upon the material provided herein. There are no representations or warranties made herein by Company or the agents, if any, of the proposed offering of any securities or debt instruments in the Company (the “Agents”) and investors will only be able to rely on the representations and warranties contained in the subscription agreement to be entered into at the time of sale of the securities. There are certain risks inherent in an investment in the securities of Company that prospective investors should carefully consider before investing in the securities of the Company. This document constitutes an offering of the securities described herein only in those jurisdictions and to those persons where and to whom they may be lawfully offered for sale, and only by persons permitted to sell these securities. This document is not, and under no circumstances is it to be construed as an advertisement or a public offering of these securities. This document is personal to each offeree and does not constitute an offer to any other person or to the public generally to subscribe for or otherwise acquire any of the securities referred to herein. No securities regulatory authority or similar authority has reviewed or in any way passed upon the presentation or the merits of these securities and any representation to the contrary is an offence. This document has been prepared for information purposes only in order to assist prospective investors in evaluating an investment in Company . No representation, warranty or undertaking, express or implied, is made and no responsibility or liability is accepted by the Agents as to the accuracy or completeness of the information contained herein or any other information, representation, warranty or undertaking, express or implied, made by Company in connection with the offering of securities described herein. FORWARD LOOKING G INFORMATI TION: This corporate document contains statements that, to the extent that they are not historical fact, may constitute “forward-looking statements” within the meaning of applicable securities legislation. Any statements regarding future plans, objectives or economic performance of Company , or the assumption underlying any of the foregoing, constitute forward- looking information. This corporate document may use words such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, and other similar expressions to identify forward-looking statements. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this corporate document, and, accordingly, investors should not place undue reliance on any such forward-looking statements. Forward- looking information involves significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements and accordingly, should not be read as guarantees of future performance or results. Any forward-looking statements speak only as of the date on which such statement is made and each of Company and the Agents disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless required by applicable law. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of each such factors. 2
CSE:VRT | OTC:VRTHF | FRT:2VP Presentation Content 4 15 About Veritas Veritas’ Team 18 Scientific Team (CTL) 7 The Opportunity 8 Veritas’ Mission 21 Sechelt Organic Marijuana 22 9 Research Status Update Veritas’ R&D Approach 12 24 Targeted Medical Conditions Future Steps & Timelines 26 13 Financials IP Strategy 3
CSE:VRT | OTC:VRTHF | FRT:2VP An emergi ging g pharmaceutical company developing g effective cannabis therapies that targe get a variety of disease conditions such acute & chronic pain, while providing g conclu con clusive sive evid vidence ce as as to to the the efficacy fficacy of of the these se tre treatm atments ts to to doctors octors an and patie patients. ts. • A Vancouver based company tri-listed on the Canadian, German and American stock exchanges. • Veritas has established a separate research and development arm, as well as, a prospective cannabis production facility through its acquisition and partnerships with Cannevert Therapeutics Ltd. and Sechelt Organic Marijuana Inc. 4
CSE:VRT | OTC:VRTHF | FRT:2VP Unique Approach About Veritas Achievements Develop the most effective One of the leading Veritas has already proprietary cannabis Canadian companies discovered several strains strains for specific disease conducting cannabis that are being scheduled conditions (i.e., Pain, etc.). research, with Canada for human trials within the being 1 of only 3 countries next few months. Provide doctors and that are legally allowed to patients with conclusive These strains were research cannabis. science supporting the identified through vigorous efficacy of the treatments. Through its strategic chemical and animal acquisitions and studies. Targeting disease partnerships, Veritas has conditions that Veritas will The company is in the last assembled a highly patent & commercialize. review stage of receiving experienced management its ACMPR license with team and a leading team of Health Canada. scientists and argologists. 5
Strategic Partnerships & Acquisitions CSE: VRT | OTC:VRTHF | FRT:2VP Sechelt Organic Marapharm Cannevert Marijuana Inc. (SOM) Ventures Inc. Therapeutics Ltd. (CTL) Research & Deve velopment: CTL Produ Pr oduct ction ion: SOM was formed Stra Strate tegic A ic Allia lliance nce: Marapharm is is the exclusive research arm of with the sole purpose of a public company, primarily Veritas and is located at the becoming a licensed producer investing in the medical and University of British Columbia. under Canada’s Access to recreational cannabis space with Cannabis for Medical Purposes operations in both Canada and Veritas is lead by a team of (ACMPR) regulations. United States. veteran scientists with a track record of success in drug SOM’s submitted its ACMPR Highlights: development. application with Health Canada • Opening 3 dispensaries in Las in July 2014 and was recently Vegas. CTL is a private company notified that it has entered the funded by Veritas through a last review stage. • Setting up analytical testing staged acquisition process. facilities for Washington State Veritas recently acquired an Veritas has entered into a growing operations. 80% stake in CTL with an definitive agreement to acquire • Advantage: circ. 300,000 option to acquire the remaining 100% of SOM, subject to SOM square feet of growing 20%. obtaining its ACMPR license. potential. 6
The Opportunity CSE: VRT | OTC:VRTHF | FRT:2VP Many Physicians’ Prospective: • “Marijuana is NOT a prescription medicine!” • “I am RELUCTANT or UNWILLING to prescribe marijuana without knowing the risks, benefits, potential complications and drug interactions!” • “I have NO TIME to properly assess, prescribe, monitor and document these patients!” • “There is no real evidence backing up claimed efficacies of marijuana strains.” Two significant concerns have not been addressed thus far: There is little or no scientific evidence that supports therapeutic benefit claims of many • “medicinal” cannabis strains. There is limited confidence in observing consistent therapeutic benefits derived from one • batch of a cannabis to another. 7
Veritas Mission CSE: VRT | OTC:VRTHF | FRT:2VP • Discover/engineer new cannabis cultivars addressing SPECIFIC disease conditions. Develop cultivars to establish STANDARDS that • can be clinically evaluated. To be the leader in PRESCRIPTION cannabis • products and therapies, i.e., developing a reliable and trustworthy BRAND. Make Canada a world LEADER in cannabis • research and product development. Provide comprehensive scientific evidence for • doctors and patients so they can prescribe and use these strains confidently. 8
R&D Approach CSE: VRT | OTC:VRTHF | FRT:2VP 1. Chemically profile different cannabis cultivars. 2. Pharmacologically profile those cultivars in the search for disease specific strains. 3. Perform clinical trials to prove clinical utility NOT follow the traditional pharmaceutical development pathway to get to market (i.e., 10+ years). 4. Conduct basic safety and efficacy profiling of cultivars. 5. Immediately market clinically effective cultivars as prescription medicines. 9
Recommend
More recommend
